The potential of neurotrophic growth factors continues to be difficult to tease out, with companies often trying disparate indications in the search for an application for these molecules.

One example is Regeneron Pharmaceuticals Inc.'s program for Axokine, its second generation ciliary neurotrophic factor. REGN last week began Phase I trials of a metabolic indication: obesity associated with Type II diabetes.